01926nas a2200349   4500000000100000008004100001260001300042653001500055653002400070653001400094653001000108653002100118653001100139653001100150653001100161653001200172653000900184653002500193100001500218700001100233700001600244700001600260700001100276700001600287245010600303856005900409300001000468490000700478050003200485520104500517022001401562       1992                            d  c1992 Mar10aAdolescent10aAntigens, Bacterial10aCell Wall10aChild10aChild, Preschool10aFemale10aHumans10aInfant10aleprosy10aMale10aMycobacterium leprae1 aSharma V K1 aKaur S1 aVaishnavi C1 aAgnihotri N1 aKaur I1 aGanguly N K00aDetection of a Mycobacterium leprae cell wall antigen in the urine of untreated and treated patients.  uhttp://leprev.ilsl.br/pdfs/1992/v63n1/pdf/v63n1a05.pdf  a28-350 v63  aInfolep Library - available3 a<p>A total of 90 leprosy patients, 12 household contacts and 10 normal subjects were studied for the detection of Mycobacterium leprae cell wall antigen in urine using monoclonal antibody (ML30A2 IgG). In untreated multibacillary leprosy (BL-LL) the M. leprae cell wall antigen could be demonstrated in the urine of 14 (64%) patients by immunofluorescence (IF) and 22 (100%) by ELISA. In untreated paucibacillary leprosy (TT-BT), it could be demonstrated in 3 (11.5%) and in 13 (50%) patients by IF and ELISA methods respectively. All but 1 household contact (later confirmed to have BL leprosy) and all 10 normal subjects' urine was negative for M. leprae cell wall antigen by both methods. The same antigen was, however, demonstrated in urine of 50% paucibacillary patients who had received 6 months of treatment and in 68% multibacillary patients who had received 24 months of WHO recommended multidrug therapy. M. leprae cell wall antigen assays in urine will not be useful in the follow-up of leprosy patients on multidrug therapy.</p>  a0305-7518